Crucial, on-the-go drug information! From alprazolam to zolpidem—this handy guide delivers quick access to the important pharmacologic content for 80 psychotropic drugs. Organized by generic name, each monograph covers indications (including off-label use
Now with DSM-5 Content! This pocket guide delivers quick access to need-to-know information on basic behavioral theories, key aspects of psychiatric and crisis interventions, mental status assessments and exams, mental health history and assessment tools, and so much more.
The Handbook of Psychiatric Drugs is a comprehensive, clear, concise and quick reference to psychiatric drug therapies, designed to guide the clinician on the selection and implementation of treatment for mental illness. Each chapter is organised by drug class and follows a standard format for ease of use. Concise sections on pharmacology and indications for use are followed by detailed information on drug selection, initiation and maintenance of treatment and withdrawal. Adverse effects, contraindications and drug interactions are also reviewed in detail, along with issues such as treatment resistance and treatment evaluation. A handy pocket-sized drug reference, the Handbook of Psychiatric Drugs makes it easy to keep up-to-date with new developments. It is an invaluable resource for all clinicians who use psychiatric drugs to treat medical and psychiatric illness, and an informative read for all those with an interest in the subject.
More than 150,000 copies in print, 4th Edition GET THE FACTS. GET THE BEST TREATMENT. GET BETTER The Essential Guide to Psychiatric Drugs has become a classic and indispensable resource for the layperson and professional alike. Informative, accessible, and easy to use, this newly revised and updated resource presents comprehensive information on the latest drugs and research, covering most adult mental health problems. It also includes balanced information on controversial topics like the risk of suicide from antidepressants and the risk of obesity and diabetes from antipsychotics. This book will help people with psychiatric problems, as well as their concerned families and friends, to better understand when drug therapy should be considered, which drugs should be used, for how long, and what side effects are expected. Includes the latest information on: -Antidepressants -Antipsychotics -Side effects and withdrawal symptoms -Specific usage, dosage duration, and efficacy “This book…meets a critical need…for the millions of people for whom psychiatric drugs are so important.” -Herbert Pardes, past President of the American Psychiatric Association. Jack M. Gorman, M.D. has been involved in psychiatric research, teaching, and patient care for more than two decades. He has been Professor of Psychiatry at Columbia University, the Mount Sinai School of Medicine, and Harvard Medical School, and lectures frequently throughout the country. He is the author of The Essential Guide to Mental Health.
Pocket Psychiatry, a new addition to the Pocket Notebook series, is written by residents for residents. A resource for essential information, in a high-yield, easy-to-use format, designed to help students, trainees, and others navigate the initial psychiatric evaluation and management of the most commonly encountered psychiatric conditions. With an emphasis on evidence-based information, Pocket Psychiatry, provides a rare concise and accessible resource, for must-know information on hospital- and clinic-based psychiatric care — from history and physical exam to differential diagnosis testing to therapeutics — in the well known loose leaf pocket size format.
TABLE OF CONTENTS: Specific Disorders and Clinical Stuations. Foreword. Preface. 1 Introduction to Psychopharmacology. 2 Antipsychotic Drugs. 3 Antidepressant Drugs. 4 Lithium. 5 Carbamazepine and Other Anticonvulsants. 6 Benzodiazepines. 7 Other Agents: Psychostimulants, Beta-Adrenergic Blockers, and Clonidine. Index.
The first essential home reference guide of its kind, fully updated. This text, geared for both the public and the therapist, will help those who already receive treatment understand more about the side effects and possible withdrawal symptoms, and will help advise others who are considering such medication.
Put this handy guide to work in class, in clinical, and in practice. From screening and assessment tools and differential diagnosis through the most commonly ordered drugs and billing and coding, this volume in the Davis Notes Series presents the information you need every day in a pocket-sized resource.
Alcohol use disorder (AUD) is a major public health problem in the United States. The estimated 12-month and lifetime prevalence values for AUD are 13.9% and 29.1%, respectively, with approximately half of individuals with lifetime AUD having a severe disorder. AUD and its sequelae also account for significant excess mortality and cost the United States more than $200 billion annually. Despite its high prevalence and numerous negative consequences, AUD remains undertreated. In fact, fewer than 1 in 10 individuals in the United States with a 12-month diagnosis of AUD receive any treatment. Nevertheless, effective and evidence-based interventions are available, and treatment is associated with reductions in the risk of relapse and AUD-associated mortality. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder seeks to reduce these substantial psychosocial and public health consequences of AUD for millions of affected individuals. The guideline focuses specifically on evidence-based pharmacological treatments for AUD in outpatient settings and includes additional information on assessment and treatment planning, which are an integral part of using pharmacotherapy to treat AUD. In addition to reviewing the available evidence on the use of AUD pharmacotherapy, the guideline offers clear, concise, and actionable recommendation statements, each of which is given a rating that reflects the level of confidence that potential benefits of an intervention outweigh potential harms. The guideline provides guidance on implementing these recommendations into clinical practice, with the goal of improving quality of care and treatment outcomes of AUD.